Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 10330 Bangkok, Thailand. [corrected].
J Clin Endocrinol Metab. 2010 Jul;95(7):3352-9. doi: 10.1210/jc.2010-0437. Epub 2010 May 5.
Nonclassic congenital lipoid adrenal hyperplasia (lipoid CAH) is a recently recognized disorder caused by mutations in the steroidogenic acute regulatory protein (StAR) that retain partial function. Affected individuals can present with a phenotype of late onset adrenal insufficiency with only mild or minimally disordered sexual development.
The aim was to delineate the clinical spectrum of StAR mutations and correlate phenotype with StAR activity.
Four patients had nonclassic/atypical lipoid CAH. Adrenal insufficiency was manifested at birth in two patients and at 11 months and 4 yr in the other two. Three were 46,XY with underdeveloped genitalia.
The StAR gene was sequenced, mutations were recreated in expression vectors, and StAR activity was measured as pregnenolone production in COS-1 cells cotransfected with the cholesterol side-chain cleavage system. StAR mutants were expressed as N-62 StAR in bacteria, and purified proteins were tested for activity with isolated steroidogenic mitochondria and for cholesterol-binding capacity.
DNA sequencing identified mutations on all alleles. Missense mutations were R188C, G221D, L260P, and F267S; we also tested R192C described by others. The respective activities of R188C, R192C, G221D, L260P, and F267S were 8.0, 39.4, 2.4, 3.1, and 6.1% of wild-type in transfected cells, and 12.8, 54.8, 6.3, 1.8, and 9.5% with isolated mitochondria. Cholesterol binding capacities of R188C, R192C, G221D, L260P, and F267S were 6.7, 55.3, 10.2, 4.6, and 20.9%. These data are correlated to the three-dimensional structure of StAR.
There is a broad clinical spectrum of StAR mutations; StAR activities in vitro correlate well with clinical phenotypes.
非经典先天性脂肪性肾上腺增生症(lipoid CAH)是一种最近才被认识的疾病,由类固醇生成急性调节蛋白(StAR)的突变引起,这些突变保留了部分功能。受影响的个体可能表现为迟发性肾上腺功能不全的表型,只有轻微或轻度发育障碍的性发育。
旨在描绘 StAR 突变的临床谱,并将表型与 StAR 活性相关联。
4 名患者患有非典型/非典型脂肪性 CAH。两名患者在出生时表现为肾上腺功能不全,另外两名患者分别在 11 个月和 4 岁时表现为肾上腺功能不全。其中 3 名患者为 46,XY,生殖器发育不良。
对 StAR 基因进行测序,在表达载体中重建突变,并在共转染胆固醇侧链裂解系统的 COS-1 细胞中测量 pregnenolone 产生来测量 StAR 活性。N-62 StAR 在细菌中表达突变体,并使用分离的类固醇生成线粒体和胆固醇结合能力测试纯化的蛋白质的活性。
DNA 测序确定了所有等位基因上的突变。错义突变为 R188C、G221D、L260P 和 F267S;我们还测试了其他人描述的 R192C。在转染细胞中,R188C、R192C、G221D、L260P 和 F267S 的相对活性分别为野生型的 8.0%、39.4%、2.4%、3.1%和 6.1%,而用分离的线粒体的相对活性分别为 12.8%、54.8%、6.3%、1.8%和 9.5%。R188C、R192C、G221D、L260P 和 F267S 的胆固醇结合能力分别为 6.7、55.3、10.2、4.6 和 20.9%。这些数据与 StAR 的三维结构相关联。
StAR 突变有广泛的临床谱;体外 StAR 活性与临床表型很好地相关。